Dr. Lal PathLabs Limited

BSE:539524 Stock Report

Market Cap: ₹244.4b

Dr. Lal PathLabs Valuation

Is 539524 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 539524 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₹1.40k
Fair Value
108.5% overvalued intrinsic discount
25
Number of Analysts

Below Fair Value: 539524 (₹2922.3) is trading above our estimate of fair value (₹1401.77)

Significantly Below Fair Value: 539524 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 539524?

Key metric: As 539524 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 539524. This is calculated by dividing 539524's market cap by their current earnings.
What is 539524's PE Ratio?
PE Ratio50.2x
Earnings₹4.87b
Market Cap₹244.39b

Price to Earnings Ratio vs Peers

How does 539524's PE Ratio compare to its peers?

The above table shows the PE ratio for 539524 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average59.4x
METROPOLIS Metropolis Healthcare
67.4x23.38%₹97.7b
VIJAYA Vijaya Diagnostic Centre
73.2x20.08%₹104.8b
539871 Thyrocare Technologies
63.1x26.22%₹57.7b
KRSNAA Krsnaa Diagnostics
34x26.38%₹26.4b
539524 Dr. Lal PathLabs
50.2x10.17%₹244.4b

Price-To-Earnings vs Peers: 539524 is good value based on its Price-To-Earnings Ratio (50.2x) compared to the peer average (59.4x).

Price to Earnings Ratio vs Industry

How does 539524's PE Ratio compare vs other companies in the IN Healthcare Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
542918 Gian Life Care
4xn/aUS$1.80m
No more companies available in this PE range
539524 50.2xIndustry Avg. 50.0xNo. of Companies8PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 539524 is expensive based on its Price-To-Earnings Ratio (50.2x) compared to the Indian Healthcare industry average (50.1x).

Price to Earnings Ratio vs Fair Ratio

What is 539524's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

539524 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio50.2x
Fair PE Ratio38.9x

Price-To-Earnings vs Fair Ratio: 539524 is expensive based on its Price-To-Earnings Ratio (50.2x) compared to the estimated Fair Price-To-Earnings Ratio (38.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 539524 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹2,922.30
₹3,078.24
+5.34%
13.38%₹3,760.00₹2,110.00n/a25
Jul ’26₹2,774.70
₹3,079.40
+10.98%
12.92%₹3,700.00₹2,110.00n/a25
Jun ’26₹2,789.85
₹3,092.60
+10.85%
13.41%₹3,770.00₹2,110.00n/a25
May ’26₹2,766.50
₹3,103.44
+12.18%
13.65%₹3,770.00₹2,110.00n/a25
Apr ’26₹2,403.25
₹3,105.42
+29.22%
13.08%₹3,770.00₹2,380.00n/a24
Mar ’26₹2,309.70
₹3,121.74
+35.16%
13.27%₹3,770.00₹2,380.00n/a23
Feb ’26₹2,860.60
₹3,139.96
+9.77%
13.86%₹3,770.00₹2,286.00n/a23
Jan ’26₹3,048.15
₹3,210.13
+5.31%
13.39%₹3,770.00₹2,286.00n/a23
Dec ’25₹3,004.10
₹3,210.13
+6.86%
13.39%₹3,770.00₹2,286.00n/a23
Nov ’25₹3,088.55
₹3,210.13
+3.94%
13.39%₹3,770.00₹2,286.00n/a23
Oct ’25₹3,413.55
₹3,134.09
-8.19%
14.46%₹3,770.00₹2,286.00n/a23
Sep ’25₹3,422.35
₹3,134.09
-8.42%
14.46%₹3,770.00₹2,286.00n/a23
Aug ’25₹3,098.95
₹2,606.18
-15.90%
11.45%₹3,500.00₹2,141.00n/a22
Jul ’25₹2,825.70
₹2,542.67
-10.02%
9.19%₹2,900.00₹2,141.00₹2,774.7021
Jun ’25₹2,647.00
₹2,514.29
-5.01%
11.60%₹2,900.00₹1,695.00₹2,789.8521
May ’25₹2,372.40
₹2,449.30
+3.24%
11.32%₹2,900.00₹1,670.00₹2,766.5020
Apr ’25₹2,287.20
₹2,439.00
+6.64%
12.93%₹3,181.00₹1,670.00₹2,403.2518
Mar ’25₹2,329.65
₹2,420.39
+3.89%
13.92%₹3,181.00₹1,670.00₹2,309.7018
Feb ’25₹2,498.50
₹2,378.50
-4.80%
16.14%₹3,181.00₹1,564.00₹2,860.6018
Jan ’25₹2,576.05
₹2,387.06
-7.34%
14.42%₹3,080.00₹1,676.00₹3,048.1517
Dec ’24₹2,740.05
₹2,371.67
-13.44%
14.36%₹3,080.00₹1,676.00₹3,004.1018
Nov ’24₹2,377.00
₹2,178.17
-8.36%
17.04%₹2,800.00₹1,432.00₹3,088.5518
Oct ’24₹2,522.10
₹2,164.83
-14.17%
17.06%₹2,800.00₹1,432.00₹3,413.5518
Sep ’24₹2,200.75
₹2,119.32
-3.70%
16.93%₹2,735.00₹1,432.00₹3,422.3519
Aug ’24₹2,347.95
₹2,104.05
-10.39%
17.34%₹2,735.00₹1,432.00₹3,098.9519
Jul ’24₹2,258.65
₹1,939.79
-14.12%
17.94%₹2,525.00₹1,187.00₹2,825.7019
AnalystConsensusTarget
Consensus Narrative from 25 Analysts
₹3.07k
Fair Value
4.9% undervalued intrinsic discount
25
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/12 17:01
End of Day Share Price 2025/07/11 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dr. Lal PathLabs Limited is covered by 49 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Ashwin MehtaAmbit Capital
Nitin BhasinAmbit Capital